Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

6

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Delta opioid receptor

6

Kappa opioid receptor

6

Mu opioid receptor

6

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1953

6

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Pain

6

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Palliative

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Germany

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

EPA CompTox

4

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

5

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LEVORPHANOL

27618J1N2X

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Delta opioid receptor

Kappa opioid receptor

Mu opioid receptor

Conditions:

Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic is appropriate. It is a potent synthetic opioid mu-...

receptor agonist similar in action to morphine. Like other opioid mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists, levorphanol produces euphoria or has a positive effect on mood in many individuals.

LEVORPHANOL HYDROCHLORIDE

1TNM58GT5U

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Delta opioid receptor

Kappa opioid receptor

Mu opioid receptor

Conditions:

Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic is appropriate. It is a potent synthetic opioid mu-...

receptor agonist similar in action to morphine. Like other opioid mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists, levorphanol produces euphoria or has a positive effect on mood in many individuals.

RACEMORPHAN HYDROBROMIDE HEMIHYDRATE

V6H50N056L

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1953

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Delta opioid receptor

Kappa opioid receptor

Mu opioid receptor

Conditions:

Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic is appropriate. It is a potent synthetic opioid mu-...

receptor agonist similar in action to morphine. Like other opioid mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists, levorphanol produces euphoria or has a positive effect on mood in many individuals.

LEVORPHANOL HYDROBROMIDE

SE8SSX6K7S

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Delta opioid receptor

Kappa opioid receptor

Mu opioid receptor

Conditions:

Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic is appropriate. It is a potent synthetic opioid mu-...

receptor agonist similar in action to morphine. Like other opioid mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists, levorphanol produces euphoria or has a positive effect on mood in many individuals.

LEVORPHANOL TARTRATE ANHYDROUS

WCB1I20F1K

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Delta opioid receptor

Kappa opioid receptor

Mu opioid receptor

Conditions:

Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic is appropriate. It is a potent synthetic opioid mu-...

receptor agonist similar in action to morphine. Like other opioid mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists, levorphanol produces euphoria or has a positive effect on mood in many individuals.

LEVORPHANOL TARTRATE

04WQU6T9QI

Export Data
Search for Structure

Status:

US Approved Rx (2021)

First approved in 1953

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Delta opioid receptor

Kappa opioid receptor

Mu opioid receptor

Conditions:

Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic is appropriate. It is a potent synthetic opioid mu-...

receptor agonist similar in action to morphine. Like other opioid mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists, levorphanol produces euphoria or has a positive effect on mood in many individuals.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1